Report this content

Oslo, Norway (02 June 2020) — Reference is made to the stock exchange notice dated 29 May 2020 regarding the initial response to the offers by Kappa Bioscience to acquire shares in NattoPharma ASA (“NattoPharma”) where the full Board of Directors in NattoPharma unanimously found that the Offer Price substantially undervalues the Company and its underlying values.

To further investigate value maximization alternatives for its shareholders, NattoPharma has engaged ABG Sundal Collier ASA to conduct a strategic review of the company. No assurance can be given regarding the outcome or timing of the process. NattoPharma will update shareholders and other stakeholders as and when relevant.


For more information, please contact:

Kjetil Ramsøy

CEO, NattoPharma


This information is subject to the disclosure requirements of section 5-12 of the Securities Trading Act.

Documents & Links